No Data
No Data
Express News | SeaStar Medical Estimates US Total Addressable Market For Its Proprietary, Patented Selective Cytopheretic Device In Five Clinical Indications Of $25B - $33B
SeaStar Medical Projects Multibillion-Dollar Market Potential for Its Selective Cytopheretic Device in Initial Target Indications
SeaStar Medical To Discuss Business Progress And Updates Tomorrow
SeaStar Medical Announces Activation of Sentara Norfolk General as Active Site
Express News | SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult Aki Pivotal Trial
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024
No Data